baber/WOPTO huggingface dataset:
Patent JP-3908790-B2 (JP)
IPC: A61P25/00
Filed: 1997-10-22
Granted: 2007-04-25
Abstract: PCT No. PCT/EP97/05843 Sec. 371 Date Apr. 23, 1999 Sec. 102(e) Date Apr. 23, 1999 PCT Filed Oct. 22, 1997 PCT Pub. No. WO98/17672 PCT Pub. Date Apr. 30, 1998Compounds of the formula I in which R1 is hydroxyl or an aliphatic, araliphatic or aromatic radical, X is a divalent aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, araliphatic, heteroarylaliphatic or aromatic radical, R2 is hydrogen or an aliphatic or araliphatic radical, alk is lower alkylidene and R3, R4 and R5 independently of one another are hydrogen, lower alkyl, halogen, trifluoromethyl, cyano or nitro, and their salts can be used for the treatment of pathological conditions which respond to blockage of excitatory amino acid receptors, and for the production of pharmaceutical preparations.
Patent JP-3787601-B2 (JP)
IPC: C08F220/28
Filed: 1993-04-21
Granted: 2006-06-21
Abstract: PCT No. PCT/EP93/00967 Sec. 371 Date Dec. 9, 1994 Sec. 102(e) Date Dec. 9, 1994 PCT Filed Apr. 21, 1993 PCT Pub. No. WO93/23443 PCT Pub. Date Nov. 25, 1993The invention relates to a process for the production of two-coat finishes, in which a pigmented aqueous basecoat is applied, the basecoat obtained is coated over with a clearcoat, and basecoat and clearcoat are baked together. The process according to the invention is distinguished in that the aqueous basecoat contains a polyacrylate resin which has been prepared using furfuryl acrylate and/or furfuryl methacrylate.
Patent JP-3394261-B2 (JP)
IPC: C01B35/12
Filed: 1997-01-17
Granted: 2003-04-07
Abstract: The present invention relates to a rare-earth borate, to a precursor thereof, to processes for their preparation and to the use of this borate as a luminophore.The rare-earth borate and the precursor thereof are characterized in that they are in the form of cubic, parallelepipedal or spherical particles and in that they have a dispersion index of not more than 0.8. According to one embodiment of the invention, the borate is a red luminophore.The process for the preparation of the precursor is characterized in that a rare-earth carbonate or hydroxycarbonate is reacted with boric acid, the reaction medium being in the form of an aqueous solution. The borate is obtained by calcination of the precursor.
Patent JP-2977286-B2 (JP)
IPC: A23J1/00
Filed: 1997-01-29
Granted: 1999-11-15
Abstract: Protein isolates having a high protein content and low residual fat content are provided in substantially non-denatured form by extracting an oil seed meal having a significant fat content, particularly canola meal, with an aqueous food grade salt solution to cause solubilization of protein and fat in the oil seed meal and form an aqueous protein solution. Following separation of this solution from the residual oil seed meal, fat is removed from the aqueous protein solution by chilling the aqueous protein solution and removing the fat which separates. The protein concentration of the defatted protein solution is increased while the ionic strength is maintained substantially constant. A further fat removal operation may be carried out on the concentrated protein solution followed by dilution to an ionic strength below about 0.2 to cause the formation of discrete protein particles in the aqueous phase in the form of protein micelles. These protein micelles are settled to form a mass of protein isolate in the form of an amorphous, sticky gelatinous, gluten-like protein micellar mass, which is separated from supernatant and dried to a proteinaceous powder.
Patent JP-4594453-B2 (JP)
IPC: A61F2/91
Filed: 1998-02-17
Granted: 2010-12-08
Abstract: The tubular flexible body has a wall (3) with a web structure (4) with a number of abutting cells (18,19) bounded by the webs, with at least one spring member (22) per cell. The spring members are preferably formed by bending the webs (7) in a hairgrip shape, with straight portions leading to adjacent cells. The pattern of webs (5,6) is formed by a number of loops (15-17). Each has straight sections (8,9) and a bent section (10), the straight sections enclosing an acute angle. Spring members and the loops define cells.
Patent JP-4017675-B2 (JP)
IPC: B01D29/96
Filed: 1998-01-14
Granted: 2007-12-05
Abstract: A filter comprising a housing, which consists of at least two housing parts, and a filter element attached inside the housing. The invention provides for at least one latch element by means of which a detachable latched connection can be established between the filter element and at least one of the housing parts.
Patent JP-3325902-B2 (JP)
IPC: G02B5/08
Filed: 1997-09-04
Granted: 2002-09-17
Abstract: A heat formable mirror is formed by sputter depositing upon a sheet such as glass a reflective coating utilizing a base layer of silicon or a combination of silicon and stainless steel films, a reflective layer formed of a reflective metallic film such as niobium, titanium or aluminum, and a protective layer comprising preferably silicon nitride. The resulting mirror can be heat formed at elevated temperatures to form a curved mirror having a reflective coating free of objectionable defects.
Patent ES-2323565-B2 (ES)
Title: Tecnica y dispositivo para conformar el espectro de ganancia de brillouin en guias de onda opticas.
Inventor: GALINDEZ JAMIOY CARLOS AUGUSTO
IPC: G01J3/44
Filed: 2009-02-25
Granted: 2010-01-12
Abstract: Técnica y dispositivo para conformar el espectro
de ganancia de Brillouin en guías de onda ópticas. 
     Técnica y dispositivo para conformar el espectro
de ganancia del efecto Brillouin en guías de onda ópticas (en
adelante guías). Inyectando una radiación luminosa o "bombeo"
en guías, se puede inducir  otra radiación -dispersión (scattering)
de Brillouin- centrada en otra  frecuencia. Esta dispersión puede
ser espontánea o estimulada por otra  radiación
contra-propagante ("semilla") y amplificarla en
la banda espectral  de ganancia de Brillouin cuyo perfil depende de
las propiedades de la guía  y del bombeo. 
     Esta invención propone la conexión de N guías
concatenadas y/o en estrella,  bombeadas todas ellas con la/s
misma/s fuente/s de bombeo como técnica  para conformar la respuesta
espectral de Brillouin del conjunto de guías  que constituyen el
dispositivo base. Puede emplearse en la elaboración  de dispositivos
y subsistemas ópticos (ópticamente sintonizables o no).  Puede
implementarse en tecnología de fibra óptica y usarse para
amplificación,  filtrado, medida y en general, procesado de señales
ópticas.
Patent IE-S86423-B2 (IE)
Title: Tassel for blind cords
Inventor: MARTINEZ JUAN MIGUEL BORRAS
IPC: E06B9/00
Filed: 2013-05-22
Abstract: A tassel (1) for blind cords comprises at least two independent parts (11,12) associated to the ends of the operating cords (21,22) of the blind and some means (3) to retain the mentioned separate pieces (11,12) in an assembled position which makes a tassel (1) to operate the blind cords, and the splitting of the parts (11,12) when there is a force applied to the cords (21,22) associated to the parts (11,12); the means (3) to retain the independent parts (11,12), that makes the tassel (1), are made of a retention elastic piece (3), which embraces the outside and tends to keep them grouped in an assembled position. <Figure 2>
Patent AU-2001234025-B2 (AU)
Title: Mutated cyclin g1 protein
Inventor: HALL FREDERICK L
IPC: C12N5/09
Filed: 2001-03-01
Granted: 2005-07-07
Abstract: Methods of treating tumors, preventing restenosis, and treating hyperplasias, corneal haze, and cataracts by administering to an animal a mutated cyclin G1 protein. The mutated cyclin G1 protein may be administered to an animal by administering to an animal an expression vehicle, such as a retroviral vector comprising a gene construct encoding a mutated cyclin G1 protein.
Patent AU-2001276672-B2 (AU)
Title: Use of the combination of nicotinic acid or derivatives with riboflavin in the manufacture of a medicament for the treatment of primary headaches
Inventor: VALLETTA GIAMPIERO
IPC: A61P43/00
Filed: 2001-07-20
Granted: 2006-06-01
Abstract: Use of a combination of two vitamin compounds, i.e. riboflavin (also known as vitamin B<SUB>2</SUB>) and nicotinic acid (also referred to as niacin) or, as an alternative thereto, the corresponding amide, i.e. niacinamide or nicotinamide (also known as vitamin PP) for the treatment of various forms of primary headache, such as classical migraine or migraine with an aura, common migraine or migraine without an aura, complicated migraine and cluster headache or histamine headache. The invention also concerns compositions for the treatment of primary headaches which are based on the two aforesaid active ingredients.
Patent AU-2001285196-B2 (AU)
Title: 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(ene)oic acid as therapeutic agents
Inventor: BURK ROBERT M
IPC: A61K31/5575
Filed: 2001-08-22
Granted: 2006-02-02
Abstract: The invention relates to the use of cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and carbamoyloxy as therapeutic agents e.g. as ocular hypotensives. The compounds used in accordance with the invention are represented by the following formula I:wherein a wavy segments indicate either the alpha (alpha) or beta (beta) configuration; the dashed bond represents a double bond or a single bond; Ar is selected from the group consisting of aryl or heteroaryl radicals having from 4 to 10 carbon atoms and substituted derivatives of said aryl and heteroaryl radicals; n is 0 or an integer of from 1 to 4; x and y are 1 or 0, provided that when x is 1, y is 0 and when x is 0, y is 1; R1 is hydrogen or a lower alkyl radical or a substituted lower alkyl radical having up to six carbon atoms; X is selected from the group consisting of -OR1 and -N(R1)2; Y is =O or represents 2 hydrogen radicals, and the 9 and/or 11 esters thereof and/or the pharmaceutically acceptable salts of said compounds and/or esters.
Patent AU-2003204731-B2 (AU)
Title: Polyurethane-polyurea dispersions
Inventor: GURTLER CHRISTOPH
IPC: C08G18/80
Filed: 2003-06-16
Granted: 2007-06-14
Abstract: Post-crosslinkable polyurethane-polyurea dispersion comprises polyisocyanate, polymeric polyol having average molar weight of 400- 6000, optionally mono- or polyalcohol or mono- or polyamine having average molar weight of up to 400, at least one blocking agent, and at least one compound chosen from compounds having at least one ionic or potentially ionic group and nonionically hydrophilicizing compounds.  Post-crosslinkable polyurethane-polyurea dispersion comprises polyisocyanate, polymeric polyol having average molar weight of 400-6000, optionally mono- or polyalcohol or mono- or polyamine having average molar weight of up to 400, at least one blocking agent, and at least one compound chosen from compounds having at least one ionic or potentially ionic group and nonionically hydrophilicizing compounds. At least 20 wt.% of the blocking agent comprises aralkylamine.  Independent claims are included for the following:  (1) method for producing one of paints and coating compositions, sizes and glass fiber sizes;  (2) coating compositions, sizes and glass fiber sizes, comprising the post-crosslinkable polyurethane-polyurea dispersion;  (3) substrate coated with coating composition; and  (4) glass fibers sized with size comprising the dispersion.
Patent AU-2003231661-B2 (AU)
Title: Pharmaceutical preparation with RNA as hemostasis cofactor
Inventor: NAKAZAWA FUMIE
IPC: A61P7/04
Filed: 2003-08-06
Granted: 2010-05-27
Abstract: A composition for promoting coagulation of blood comprising a natural or synthetic RNA, or its fragments or analogs, e.g. peptide nucleic acids, ribozymes or RNA aptamers (collectively (A)), is new. Independent claims are also included for: (1) composition for promoting fibrinolysis or for inhibiting coagulation containing one or more agents (B) that degrade RNA or inhibitory compounds with RNase activity or RNA-complexing capacity; (2) diagnostic process for detecting post-operative hypercoagulative states, complication of pregnancy, tumor status, acute myocardial infarction or sepsis by detecting increased levels of plasma RNA, relative to healthy subjects; and (3) diagnostic agent, containing (A), for qualitative or quantitative determination of the blood coagulation factor VII-activating protein (FSAP) or its proenzyme. ACTIVITY : Antibacterial; Immunosuppressive; Hemostatic; Anticoagulant; Thrombolytic; Cerebroprotective. No biological data given. MECHANISM OF ACTION : Modulating the effects of RNA, released from injured tissue or cells, which is an important initial cofactor in the induction of both extrinsic and intrinsic coagulation pathways; specifically RNA binds to and activates the factor VII-activating protease (FASP). RNA from different sources was added to a turbidimetric coagulation test and the recalcification time (RT) measured. All types of RNA tested significantly reduced RT (no figures given), but pretreatment of RNA with RNase destroyed this effect.
Patent AU-2003233962-B2 (AU)
Title: Water-soluble copolymers based on olefinic sulfonic acids, method for the production thereof and use of the same
Inventor: FENCHL ANDREA
IPC: C08F220/58
Filed: 2003-04-09
Granted: 2008-05-15
Abstract: Water soluble copolymers based on olefinic sulfonic acids, olefinic dicarboxylic acids, vinyl amides, vinyl ethers, and/or allyl ethers and or bisacryl derivatives are new.  Water soluble copolymers based on olefinic sulfonic acids containing (wt.%):(a) structural units (5-93) of formula (Ia) and (Ib): R1  =  H or 1-5C alkyl, R2  =  1-20C alkylene, 1-20C carboxy-alkylene, 1-20C carboamido-alkylene or phenylene, M  =  H, ammonium, or mono-, di-, or trivalent metal cation, and x  =  1-3, (b) structural units (1-50) of formula (IIa) and IIb):R3 and R4 = COO-=(Mx+)1/x or together = (IIc):, R5  =  COO-=(Mx+)1/x, M  = H, ammonium or mono-, di-, or trivalent metal cation, and x  =  1-3, (c) structural units (5-93) of formula (III): R6  =  H or 1-8C alkyl, R7 and R8  =  H or 1-10C alkyl, or together = (CH2)y, y  =  3-7, (d) structural units (1-25) of formula (IVa): and/or (IVb) and/or (IVc):R9 = H or 1-8C alkyl, R10  =  1-10C alkyl, 1-10C aminoalkyl, 1-20C hydroxyalkyl, 1-4C alkyl, or OH-terminated mono- or 2-3C polyalkyleneoxy (with 1-400 alkyleneoxy units), 7-20C alkylaryl, 7-20C hydroxyalkylaryl, 6-10 C aryl, 8-10C hydroxyaryl, R11 to R13  =  H or 1-5C alkyl, and R14 = H, 1-20C alkyl, 1-10C aminoalkyl, 1-20C hydroxyalkyl, 1-4C alkyl- or OH-terminated mono- or 2-3C polyalkyleneoxy (with 1-400 alkyleneoxy units), 7-20C alkylaryl, 7-20C hydroxyalkylaryl, 8-10C aryl, 8-10C hydroxyaryl or optionally OH group substituted 1-20C alkylenesulfonic acids and their ammonium, alkali, or alkali earth salts,=R15 = (IVd): R16 = H, Me, X  =  O, NH,=n = 1-6, r,s  = 0-5, t  =  1 or 3, u  =  1-50,R6 = as above, and components (a) to (d) add up to 1-wt.%. An Independent claim is included for preparation of the copolymer by polymerization of monomers of formula (Ia) and/or (Ib):R1, R2, M, x = as above, of formula (IIa) and/or (IIb):R3, R4, M, x = as above, of formula (III):R6,R7,R8, y = as above, of formula (IVa) and/or (IVb):R9,R10, R11 to R13, R14 = as above, R15 = (IVd):R16, X, N, r,s, t, and u = as above, and R6 = as above, in the solid state or in solution at -5 to 120degreesC.
Patent AU-2003238718-B2 (AU)
Title: Apparatus for preparing a consumable beverage with a fine-bubbled foam layer
Inventor: BROUWER GUSTAAF FRANS
IPC: A47J31/06
Filed: 2003-06-12
Granted: 2007-09-13
Abstract: The equipment (1) has a nozzle (4) which sprays a jet (12) of the beverage dispensed under pressure from a beverage storage unit (2) towards a collection housing (14) formed with a chamber (16) in which a jet impact element (20) is positioned facing the nozzle. The jet of beverage spouts against the convex top (22) of the jet impact element and leaves the chamber as fine bubbled foam layer. Independent claims are also included for the following: (1) preparation method of consumable beverage with fine bubbled foam layer; (2) for beverage unit containing collection housing, nozzle and container; and (3) assembly comprising the beverage unit and a pad.
Patent AU-2003276746-B2 (AU)
Title: Method of multiplexing logical channels in mobile communication system and apparatus thereof
Inventor: YI SEUNG-JUNE
IPC: H04W4/06
Filed: 2003-11-06
Granted: 2006-09-28
Abstract: For multiplexing logical channels, at least two common logical channels of the same type are multiplexed to the same transport channel in a mobile communication system. When the transport channel carries different types of logical channels, a Common Logical channel Identifier (CLI) is defined and inserted into a MAC PDU header so that the different logical channels can be identified. Multiple services having a different quality of service (QoS) or multiple streams of different QoS in the same service can be handled and provided to user equipment (UE).
Patent AU-2003283527-B2 (AU)
Title: Manufacture of electrochemical sensors by moveable flat screen printing
Inventor: SIM ANDREW GRAHAM
IPC: G01N27/30
Filed: 2003-10-30
Granted: 2009-06-04
Abstract: The present invention described a method of preconditioning a substrate in a web manufacturing process wherein the web manufacturing process includes a plurality of printing steps, the method comprising the steps of moving the substrate through the web manufacturing process under tension; heating the substrate as the substrate is passed through the printing steps, wherein the substrate temperature does not exceed a first predetermined temperature during the printing steps; and passing the substrate into a preconditioning station wherein the substrate is heated to a second temperature which exceeds the first temperature.
Patent AU-2004247418-B2 (AU)
Title: 1.3.4-triaza-phenalene and 1,3,4,6-tetraazaphenalene derivatives
Inventor: LUK KIN-CHUN
IPC: C07D471/06
Filed: 2004-04-26
Granted: 2009-11-05
Abstract: Novel 1,3,4-triaza-phenalene and 1,3,4,6-tetraazaphenalene derivatives are disclosed. These compounds inhibit epidermal growth factor receptor ("EGFR") tyrosine kinase. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful, inter alia, in the treatment or control of cancer, in particular solid tumors. This invention also relates to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors.
Patent AU-2004288591-B2 (AU)
Title: Framework to enable integration of anti-spam technologies
Inventor: WALLACE ANDREW J
IPC: G06Q10/00
Filed: 2004-07-26
Granted: 2009-12-24
Abstract: A method that enables multiple spam detection solutions to be deployed in a manageable and rational manner to determine if a message is spam is presented. A framework invokes anti-spam filters to analyze the message and return confidence levels of whether a message is spam. The framework evaluates the highest confidence level against a set of defined thresholds. If the highest confidence level is greater than the highest threshold set by the administrator, the action specified for the highest threshold is taken. The highest confidence level is also compared against all thresholds and the action associated with the nearest threshold that has been exceeded is taken.
Patent AU-2004299071-B2 (AU)
Title: Instruments and methods for bone anchor engagement and spinal rod reduction
Inventor: VARIEUR MICHAEL S
IPC: A61B/
Filed: 2004-12-15
Granted: 2010-06-17
Abstract: An instrument for engaging a bone anchor may include a first implant engaging member having a proximal end and a distal end and a second implant engaging member having a proximal end and a distal end. The second implant engaging member may be pivotally connected to the first implant engaging member about a pivot point located proximate the distal ends of the first and second implant engaging members. Manipulation of the proximal ends of the first and second implant engaging member can cause each of the distal ends to rotate about the pivot point to engage at least a portion of a bone anchor. A rod adjusting tool may be connectable to the bone anchor engaging tool and may be axially adjustable relative to the bone anchor tool to adjust a spinal rod relative to the bone anchor.
Patent AU-2004320622-B2 (AU)
Title: Chimeric gapped oligomeric compositions
Inventor: DANDE PRASAD
IPC: C12N15/11
Filed: 2004-06-03
Granted: 2012-06-14
Abstract: The present invention provides double stranded compositions wherein the first strand comprises three different regions and the second strand is native RNA. Each region has native or modified ribofuranosyl sugar moieties that are different than those of the other two regions. At least a portion of the first oligomeric compound is complementary to and hybridizes to a nucleic acid target. The present invention also provides methods for modulating gene expression using the modified oligomeric compounds and compositions of oligomeric compounds.
Patent AU-2005215122-B2 (AU)
Title: Use of meloxicam for the treatment of respiratory diseases in pigs
Inventor: IOANNIS PAPATSAS
IPC: A61K45/06
Filed: 2005-02-16
Granted: 2011-08-11
Abstract: The invention relates to the use of meloxicam or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment or prevention of respiratory diseases in pigs.
Patent AU-2005220177-B2 (AU)
Title: 2-hydroxy-3-alkoxypropyl sulfides, sulfones, and sulfoxides: new surface active agents
Inventor: YACOUB KHALIL
IPC: C09D7/47
Filed: 2005-10-04
Granted: 2007-07-26
Abstract: Compositions containing surfactant compounds according to formula (1)  
R 4 OCH 2 CH(OH)CR 2 R 3 ZR 1 (I)  
wherein Z is S, SO, or SO 2 , can have a range of equilibrium and/or dynamic surface tensions and a range of foaming performance attributes, depending upon the particular values of Z, R 1 , R 2 , R 3 , and R 4 . The compounds of formula (I) may be prepared by a process that includes reaction of a thiol with a glycidyl ether.
Patent AU-2005285109-B2 (AU)
Title: Bicyclic anilide spirolactam CGRP receptor antagonists
Inventor: ZHANG XUFANG
IPC: A61K31/4747
Filed: 2005-09-09
Granted: 2011-03-03
Abstract: The present invention is directed to compounds of Formula I: (where variables A1, A2, B, J, K, m, n, R4, R5a, R5b and R5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Patent AU-2005295010-B2 (AU)
Title: Ultrasonic surgical instrument
Inventor: NEUROHR MARK A
IPC: A61B18/18
Filed: 2005-10-07
Granted: 2012-05-31
Abstract: An ultrasonic clamp coagulator assembly that is configured to permit selective cutting, coagulation and clamping of tissue during surgical procedures. An elongated portion of the instrument can be configured for endoscopic applications and has an outside diameter of less than 6mm. The construction includes a clamping mechanism, including a clamp arm pivotally mounted at the distal portion of the instrument, which is specifically configured to create a desired level of tissue clamping forces, exceeding 4 pounds when the trigger is fully closed. The clamping mechanism includes a two-piece pad design and pad material that enables the higher tissue clamping forces and a force­limiting mechanism that effectively smooths out abusive tissue forces. The assembly also features hand activation configured to provide an ergonomical grip and operation for the surgeon. Hand switches are placed in the range of the natural swing of the surgeon's thumb, whether gripping the surgical instrument right-handed or left handed.